Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon. Academic officials and examination authorities have advised students and parents to review the official notification for verified dates, eligibility norms, and documentation requirements. Further updates will be issued through the official portal.